Page 107 - Immunization Practices News Today

The Tri-Agencies issued Frequently Asked Questions addressing the impact of the Braidwood decision on the ACA's preventive care mandate, including guidance on certain preventive care services...

The vaccine should be available in the fall.

The vaccine should be available in the fall.

RSV causes little illness in most healthy adults, but those with underlying conditions are at risk. This first vaccine is designed for adults 60 and older, but other RSV vaccines and drugs are in the works, including a vaccine to protect infants.

The FDA approved the first RSV vaccine Wednesday, called Arexvy, which is designed to be given as a single shot to adults 60 and over.

The FDA approved Arexvy, the world's first vaccine for respiratory syncytial virus (RSV), on Wednesday. Manufactured by GlaxoSmithKline Pharmaceuticals, the RSV vaccine is approved for use in people ages 60 and older.

The vaccine should be available in the fall.

The vaccine is the first to prevent lower respiratory tract disease caused by respiratory syncytial virus (RSV) for adults 60 and older.

The Food and Drug Administration on Wednesday approved Arexvy, the world's first respiratory syncytial virus (RSV) vaccine — a scientific breakthrough 60 years in the making.

The vaccine should be available in the fall.